Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00079924

Enrollment

200

Registered

2004-03-19

Start date

2004-11-30

Completion date

2007-05-31

Last updated

2007-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Osteoporosis

Brief summary

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.

Interventions

DRUGteriparatide

DRUGaldrenodate

DRUGraloxifene

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Postmenopausal women aged at least 50 years * A previous clinical diagnosis of osteoporosis * At high risk for fracture * Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na

Exclusion criteria

* History of metabolic bone disease other than osteoporosis * History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma

Design outcomes

Primary

Measure	Time frame
Change in calcium values after beginning teriparatide	—

Secondary

Measure	Time frame
Frequency of hypercalcemia, various calcium assessments, change in bone mineral density and tests of bone formation and resorption	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026